Clinical trials are the primary way we determine whether experimental treatments are safe and effective. Increasing diversity better reflects the range of populations that will use the therapy, or vaccine, being studied. Medications can affect various racial and ethnic groups differently, sometimes to the extent that the U.S. Food and Drug Administration (FDA) recommends separate prescribing instructions.
Clinical trials also provide early access to experimental treatments for a range of diseases. Prioritizing diversity within studies will help ensure people of color are not left out of these potentially lifesaving opportunities and move us closer to a more equitable healthcare system.
